Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ONC.TO
- Price
- 0.88
- Stock movement up
- +0.18 (25.71%)
- Company name
- Oncolytics Biotech Inc
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 67.83M
- Ent value
- 63.43M
- Price/Sales
- -
- Price/Book
- 7.49
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -17.56%
- 1 year return
- -44.65%
- 3 year return
- -23.56%
- 5 year return
- -15.64%
- 10 year return
- -21.01%
Last updated: 2025-04-12
DIVIDENDS
ONC.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 7.49 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 77.07M |
| EPS (TTM) | -0.36 |
| FCF per share (TTM) | -0.33 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -328.00K |
| Operating income (TTM) | -35.39M |
| Net income (TTM) | -27.64M |
| EPS (TTM) | -0.36 |
| EPS (1y forward) | -0.47 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 19.60M |
| Net receivables | 104.00K |
| Total current assets | 22.91M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.35M |
| Total assets | 24.26M |
| Accounts payable | 3.43M |
| Short/Current long term debt | 1.06M |
| Total current liabilities | 7.66M |
| Total liabilities | 15.21M |
| Shareholder's equity | 9.06M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -25.24M |
| Capital expenditures (TTM) | 81.16K |
| Free cash flow (TTM) | -25.33M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -305.20% |
| Return on Assets | -113.93% |
| Return on Invested Capital | -296.97% |
| Cash Return on Invested Capital | -272.08% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.73 |
| Daily high | 0.90 |
| Daily low | 0.71 |
| Daily Volume | 181K |
| All-time high | 193.80 |
| 1y analyst estimate | 6.75 |
| Beta | 1.51 |
| EPS (TTM) | -0.36 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| ONC.TO | S&P500 | |
| Current price drop from All-time high | -99.55% | -12.89% |
| Highest price drop | -99.72% | -56.47% |
| Date of highest drop | 2 Oct 2019 | 9 Mar 2009 |
| Avg drop from high | -85.52% | -11.07% |
| Avg time to new high | 206 days | 12 days |
| Max time to new high | 6133 days | 1805 days |
COMPANY DETAILS
Marketcap
67.83M
Marketcap category
Small-cap
Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Employees
0
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found